In the in vivo and in vitro experiments with ovarian cancer, FRS2 inhibitors prevented the activation of FRS2 and interrupted the FGFR signaling pathway, thereby inhibiting tumor invasion and growth 25. The gene discussed is FRS2; the disease is neoplasm.